Hyderabad-based drug major Dr Reddy’s Laboratories Ltd on Friday (October 24) reported a net profit of ₹1,347 crore for the September quarter (Q2 FY26), up 7.3% year-on-year from ₹1,256 crore, though slightly below the CNBC-TV18 poll estimate of ₹1,403.7 crore.

The company’s revenue increased 9.8% YoY to ₹8,828 crore, compared with ₹8,038 crore in the same period last year, surpassing the poll estimate of ₹8,595.4 crore.

Operating performance showed a mixed trend, with EBITDA at ₹2,010 crore, down 3.2% YoY from ₹2,076.8 crore and below the poll estimate of ₹2,208.5 crore. EBITDA margin stood at 22.8%, compared with 25.8% YoY and 25.7% expected by analysts.

For H1 FY26, consolidated revenues were ₹17,350 crore, reflecting an 11% YoY growth. Growth was broad-based across key markets, ex

See Full Page